Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.

Its mission is to make genetic medicines safer, more effective, and applicable for a wider range of treatments.